Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy
These results demonstrate the impact of tumor antigenicity on the induction of protective endogenous antitumor immunity during CD3 bsAb treatment and, importantly, show that the combination with tumor-specific vaccines improves therapeutic efficacy and installs long-term immunological memory in both "hot" and "cold" tumors.
Authors
- Gaby Schaap
- Kristel Kemper (ORCID: https://orcid.org/0000-0003-3229-6902)
- Marjolein Sluijter
- Sjoerd H. van der Burg (ORCID: https://orcid.org/0000-0002-6556-0354)
- Jim Middelburg (ORCID: https://orcid.org/0000-0002-4797-9653)
- Thorbald van Hall (ORCID: https://orcid.org/0000-0002-9115-558X)
- Janine Schuurman (ORCID: https://orcid.org/0000-0002-9738-9926)
- Katy A. Lloyd
- Vitalijs Ovcinnikovs (ORCID: https://orcid.org/0009-0006-2855-0081)
Institutions
- Leiden University Medical Center (NL)
- Genmab (Netherlands) (NL)
- Oncode Institute (NL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010331
- Citations
- 4
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- Universiteit Leiden
- Leids Universitair Medisch Centrum